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Supplementary Figure 1. Comparison of two commercially available globin mRNA reduction 
assays (GLOBINclearTM and Globin-ZeroTM) based on manufacturer’s product information 
from official webpage. In addition, GlobinLock principle and parameters are depicted.  	
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Supplementary Figure 2. Human globin mRNA secondary structure prediction. The Mfold 
web server was used to (a) predict human globin α1 (HBA1), (b) human globin α2 (HBA2) 
and (c) human globin β (HBB) self-folding. The delta G value and the globin zoom-in at the 3’-
5’ proximity region are depicted to visualize the binding site of GlobinLock or anchored oligo-T 
primer.  
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Supplementary Figure 3. Human globin mRNA secondary structure prediction. The Vienna 
RNA websuite was used to (a) predict human globin α1 (HBA1), (b) human globin α2 (HBA2) 
and (c) human globin β (HBB) self-folding. The delta G value and the globin zoom-in at the 3’-
5’ proximity region are depicted to visualize the binding site of GlobinLock or anchored oligo-T 
primer.  
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Supplementary Figure 4. The prevalence of globin mRNAs from different species was 
reduced by type 3’DNA long GlobinLock oligonucleotides, quantified by qPCR. NA indicates 
the inability to detect the specific globin with unique primers using a SYBR green qPCR 
assay. Template dilutions (10×) were used in this relative qPCR design and therefore the 
reduction effect up to ten is measured accurately according to existing dilution factor but fold 
change values above ten are out of the reported quantification range. 
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Supplementary Table 1. Used GlobinLock oligonucleotides with specific modifications and 
purifications. In addition, qPCR primers, barcoded 48-plex template-switching 
oligonucleotides for 48-plex RNA-seq experiment and globin cloning primers of different 
species are listed. 
>>> Attached as a separate file “Suppl Table 1” 
 
Supplementary Table 2. The specificity of GlobinLock with 1–100 ng of whole-blood RNA, 
using two artificial spike-in molecules. One-way ANOVA analysis together with t-test p-values 
to measure the significance based on two spike-in molecule (Spike-1 and Spike-2) detection 
rates at different whole-blood RNA input levels.  
 
 
Supplementary Table 3. The statistics for GL RNA sequencing results over five GL 
conditions and the control. RNA-seq data QC parametres from mapping (No. of raw reads per 
sample (average)) to (mRNA 5'-end capture rate (%)). The data were analyzed with unique 
molecular identifier (UMI) correction and without. The results described in the manuscript are 
without UMI correction. The analytical pipeline details are described in Methods and 
https://github.com/shka/STRTprep 
>>> Attached as a separate file “Suppl Table 3” 
 
Supplementary Table 4. Uniquely detected genes without different GlobinLock 
oligonucletoides. The top 10 uniquely expressed genes under different GlobinLock conditions 
and the GlobinLock-negative control. The mRNA’s 3’-most sequences are depicted and 
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compared with GlobinLock sequences to find possible interactions. BLASTN scores indicated 
very low specificity because the values remained <33 in a 100 scale.  
>>> Attached as a separate file “Suppl Table 4” 
 
Supplementary Table 5. The detected genes with normalized prevalence and 95% 
confidence intervals. The "Type" represents the type of tested GlobinLock oligonucleotides or 
negative control. 
>>> Attached as a separate file “Suppl Table 5” 
 
Supplementary Table 6. Alignment of high-quality Sanger re-sequencing of dog and 
zebrafish clones compared to the reference and GlobinLock molecule. Novel motifs or 
deletions are marked in red.  
>>> Attached as a separate file “Suppl Table 6” 
 
Supplementary Table 7. The high-quality raw data of Sanger re-sequencing. 
>>> Attached as a separate file “Suppl Table 7” 
 	
